Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Autor: Mónica Patricia Cala, María Teresa Agulló‐Ortuño, Elena Prieto‐García, Carolina González‐Riano, Lucía Parrilla‐Rubio, Coral Barbas, Carmen Vanesa Díaz‐García, Antonia García, Cristina Pernaut, Jorge Adeva, María Carmen Riesco, Francisco Javier Rupérez, Jose Antonio Lopez‐Martin

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 9, Iss 2, Pp 348-357 (2018)

Abstract Background Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and ne

Externí odkaz: https://doaj.org/article/791db3b470124f629a82a0db56bc1604

Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status

Autor: Lucía Carril-Ajuria, Emeline Colomba, Carmen Romero-Ferreiro, Luigi Cerbone, Raffaele Ratta, Philippe Barthelemy, Clarisse Vindry, Aude Fléchon, François Cherifi, Elouen Boughalem, Claude Linassier, Giuseppe Fornarini, Sara E. Rebuzzi, Marine Gross-Goupil, Carolina Saldana, Maricruz Martin-Soberón, Guillermo de Velasco, Ray Manneh, Cristina Pernaut, Ana Sanchez de Torre, Ronan Flippot, Bernard Escudier, Laurence Albiges

Publikováno v: European journal of cancer (Oxford, England : 1990). 180

Background Immune checkpoint inhibitor-based combination therapy (ICI-based combination) is a new standard of care for metastatic clear cell renal cell carcinoma (mRCC) in the frontline setting. Patients with poor performance status (PS) (≥2) were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d5e3ebb7c81050c5954cf67c115ce22
https://pubmed.ncbi.nlm.nih.gov/36527973

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Autor: Jorge Adeva, Cristina Pernaut, María Carmen Riesco, Jose A. Lopez-Martin, Carolina Gonzalez-Riano, Carmen Vanesa Díaz-García, Lucía Parrilla-Rubio, Elena Prieto-García, Mónica P. Cala, Antonia García, María Teresa Agulló-Ortuño, Coral Barbas, Francisco J. Rupérez

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle. 9:348-357

Background Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative prot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb202d9dd2898e5b4ab0439c1489375f
https://doi.org/10.1002/jcsm.12270

Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies

Autor: Luis Manso Sánchez, Maria Lomas Garrido, Ana Jaén Morago, Paula Espinosa Olarte, Cristina Pernaut Sánchez, Pedro Sánchez Rovira

Publikováno v: Future oncology (London, England). 14(7s)

Although advancing age can greatly increase the complexities of treating metastatic breast cancer, chronological age alone is insufficient to determine the type or intensity of treatment. Older patients require an individualized approach that takes i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b3863a19f8df97a3d54e7cd57ea9c0
https://pubmed.ncbi.nlm.nih.gov/29611758

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

Autor: Pablo Villalba, María Apellániz-Ruiz, Luis Manso, Tomás Pascual, Mercedes Robledo, Lucía Inglada-Pérez, Eva Ciruelos, Cristina Rodríguez-Antona, Cristina Pernaut, Cecilia Cueto-Felgueroso, Carlos E. Alvarez

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)
PLoS ONE, Vol 12, Iss 7, p e0180192 (2017)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
PLoS ONE

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b971849f2cf2b987603e66263df27c4
http://hdl.handle.net/20.500.12105/5275